Number 898 • September 2020

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC, Sandoz Canada Inc., and Teva Canada Limited that the shortages for Losartan 50 mg Tablet (DIN 02388804), Sandoz-Losartan 50 mg Tablet (DIN 02313340), and Teva-Losartan 50 mg Tablet (DIN 02357968) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 9, 2020**. The following grouping was removed from the Critical Supply Product List **September 9, 2020**.

LOSARTAN POTASSIUM

50 MG TABLET

00002353504	APO-LOSARTAN	APX	\$ 0.1616
00002403331	AURO-LOSARTAN	AUR	\$ 0.1616
00002445972	BIO-LOSARTAN	BMD	\$ 0.1616
00002398842	JAMP-LOSARTAN	JPC	\$ 0.1616
00002388804	LOSARTAN	SIV	\$ 0.1616
00002405741	MINT-LOSARTAN	MPI	\$ 0.1616
00002309769	PMS-LOSARTAN	PMS	\$ 0.1616
00002313340	SANDOZ LOSARTAN	SDZ	\$ 0.1616
00002424975	SETPA-LOSARTAN	SEP	\$ 0.1616
00002357968	TEVA-LOSARTAN	TEV	\$ 0.1616
00002182874	COZAAR	MFC	\$ 1.4140

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage for Sandoz Valsartan 80 mg Tablet (DIN 02356759) has been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 9, 2020**. The following grouping was removed from the Critical Supply Product List **September 9, 2020**.

VALSARTAN

80 MG TABLET

00002414228	AURO-VALSARTAN	AUR	\$ 0.2159
00002363100	RAN-VALSARTAN	RAN	\$ 0.2159
00002356759	SANDOZ VALSARTAN	SDZ	\$ 0.2159
00002356651	TEVA-VALSARTAN	TEV	\$ 0.2159
00002244781	DIOVAN	NOV	\$ 1.3032

Alberta Blue Cross has been advised by AA Pharma Inc that the shortage for Desmopressin 0.1 mg Tablet (DIN 02284030) has been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 15, 2020**. The following grouping was removed from the Critical Supply Product List **September 16, 2020**.

DESMOPRESSIN ACETATE

0.1 MG TABLET

00002284030	DESMOPRESSIN	AAP	\$ 0.6609
00000824305	DDAVP	FEI	\$ 1.3336

Alberta Blue Cross has been advised by Actavis Pharma Company and Teva Canada Limited that the shortages for Act Nabilone 0.5 mg Capsule (DIN 02393581) and Teva-Nabilone 0.5 mg Capsule (DIN 02384884) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 19, 2020.** The following grouping was removed from the Critical Supply Product List **September 17, 2020.**

NABILONE

0.5 MG CAPSULE

00002393581	ACT NABILONE	APH	\$ 0.7756
00002380900	PMS-NABILONE	PMS	\$ 0.7756
00002384884	TEVA-NABILONE	TEV	\$ 0.7756
00002256193	CESAMET	VCL	\$ 3.4871

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



